Modulight

0,93

EUR

+7,51 %

Corporate customer

MODU

First North Finland

Medical Equipment & Services

Health Care

2.689 investorer følger denne virksomhed

+7,51%

-1,59%

-19,83%

-26,19%

-20,78%

-16,82%

-91,81%

-

-91,5%

Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.

Markedsværdi

39,63 mio. EUR

Aktieomsætning

40,65 t EUR

P/E (adj.) (24e)

-5,14

EV/EBIT (adj.) (24e)

-3,52

EV/S (24e)

7,43

Udbytteafkast, % (24e)

-

Coverage

Anbefaling

Reducer

Kursmål

0.90 EUR

Opdateret

22.10.2024

Latest research

Latest analysis report

Released: 22.10.2024

Latest extensive report

Released: 21.03.2023

Risiko

Business risk

Valuation risk

Lav

Høj

ViserAlle indholdstyper

Analytikerkommentarfor 39 minutter siden af

Modulight receives order worth 0.5 MEUR

Delivery of the order is scheduled for the second half of 2025 and the first half of 2026.

Drug development investment: Value creation through M&As and licensing agreements

Artikelfor 19 timer siden af

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Selskabsmeddelelsefor 21 timer siden

Inside Information: Modulight Has Received an Order Worth EUR 0.5 Million

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelsefor 23 timer siden

Modulight Corporation's Shareholders’ Nomination Committee Composition

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video16.12.2024, 11.00

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Regulation of drug development

Analytikerkommentar3.12.2024, 10.21 af

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Analytikerkommentar8.11.2024, 11.52 af

Pay-Per-Treatment model brings Modulight order intake

Modulight announced on Friday that it has secured contracts with a minimum cumulative value of EUR 1.5 MEUR over the next two years. The news adds further visibility to the progress of the revenue and PPT model in the coming years

Selskabsmeddelelse8.11.2024, 08.25

Inside Information: Modulight has received PPT purchase orders worth of 1.5 million dollars

Analyse22.10.2024, 06.51 af

Modulight Q3'24: No clear signs of growth yet

Modulight's Q3 report showed no clear signs of a return to growth and revenue landed below expectations. Earnings and cash flow were roughly in line with our forecasts due to lower-than-expected costs.

Modulight Q3'24 flash comment: Revenue missed expectations - profit and cash flow close to forecasts

Analytikerkommentar18.10.2024, 12.41 af

Modulight Q3'24 flash comment: Revenue missed expectations - profit and cash flow close to forecasts

Modulight's revenue was well below our expectations, but profit and cash flow were close to our forecasts. Revenue was negatively impacted by the transition to the PPT (pay-per-treatment) model and delays in prototype deliveries.

Selskabsmeddelelse18.10.2024, 10.00

Modulight: Cash flow development continued positive, progress with new business models

Modulight Q3'24 preview: Eye laser and clinical studies as revenue drivers

Analytikerkommentar16.10.2024, 06.22 af

Modulight Q3'24 preview: Eye laser and clinical studies as revenue drivers

Modulight will publish its Q3 results on Friday, October 18 at 1:00 pm EEST. We expect moderately growing revenue from Phase III clinical projects and ophthalmic lasers.

Pressemeddelelse14.10.2024, 10.00

Modulight to publish its interim report for January–September 2024 on October 18, 2024

Selskabsmeddelelse16.9.2024, 10.20

Modulight Corporation: Managers' Transactions – Jari Sillanpää

Selskabsmeddelelse16.9.2024, 10.20

Modulight Corporation: Managers' Transactions – Virpi Sillanpää

Selskabsmeddelelse11.9.2024, 10.00

Modulight Corporation: Managers' Transactions – Jari Hopsu

Selskabsmeddelelse11.9.2024, 10.00

Modulight Corporation: Managers' Transactions – Ulla Haapanen

Selskabsmeddelelse22.8.2024, 12.30

Modulight Corporation: Managers' Transactions – Lasse Orsila

Analyse19.8.2024, 08.51 af

Modulight Q2'24: Top line needs a boost

Modulight's Q2 revenue declined year-on-year and missed our forecasts. However, operating loss was lower than expected. The company had expanded its project pipeline to 30 and continued to roll out its pay-per-treatment (PPT) pricing model during the period. The model is not generating significant revenue at this time.

Selskabsmeddelelse16.8.2024, 10.02

Modulight: Implementation of the new business model progressed and cash flow improved

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.